ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China Antengene receives...
Hence then, the article about antengene announces exclusive license agreement with mpm bioimpact established k2 therapeutics for atg 106 and option for undisclosed bispecific tce was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE )
Also on site :
- Bentonville Film Festival: ‘If I Go They Will Miss Me,’ ‘Jane Elliott Against The World’ Win Top Awards – Full List
- My 60-Year-Old Mom Looks Nothing Like Her Age—These 4 Under-$25 Skincare Staples Are Her Secret
- Victoria Beckham's Father's Day Post Fuels More Questions About Brooklyn Beckham Feud